An Italian multicenter study reported real-world evidence that lumacaftor/ivacaftor is safe and effective in preschool-aged children with cystic fibrosis carrying relevant genotypes, including F508del homozygosity. The results focus on how the CFTR modulator performs earlier in pediatric life outside of traditional older-age populations. The headline development is pediatric applicability: extending safety and effectiveness data into preschool years can influence prescribing patterns and trial design for earlier CF intervention. For biotech and payers, the decision-useful angle is whether long-term tolerance and clinical gains can be achieved at younger ages, supporting broader access to disease-modifying therapy in early childhood.